ArticleEndocrine, metabolic & immune disorders drug targets2026
Exploring and Validating Prognostic Biomarkers Related to Sphingolipid Metabolism in Gastric Cancer through Machine Learning
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSphingolipid metabolism (SM) has been implicated in the progression of gastric cancer (GC). However, its potential as a prognostic biomarker in GC remains underexplored. This study investigates the feasibility of using SM to predict GC prognosis.
methodsSphingolipid metabolism-related genes (SMRGs) were extracted from the GeneCards database, and differentially expressed genes (DEGs) were identified using the TCGA-STAD and GSE84437 gastric cancer datasets. Univariate Cox regression analysis was performed to identify genes associated with survival. Lasso-Cox and random survival forest analyses were employed to identify key survival-related genes, followed by multivariate Cox regression to establish a prognostic model and calculate the sphingolipid metabolism score (SMscore). The lasso-Cox analysis further assessed the prognostic significance of clinical traits and the SMscore. Hyperparameters were optimized using machine learning models to achieve the most accurate prognostic model. The potential utility of the SMscore in GC prognosis was evaluated, and hub gene expression was validated through immunohistochemistry (IHC) staining.
resultsELOVL4, NOS3, and ABCA2 were identified as key prognostic genes from a pool of 556 SMRGs. The optimal prognostic model was developed and validated, demonstrating robust predictive performance. IHC staining revealed increased expression of ELOVL4 and NOS3 in tumor tissues, which correlated significantly with poor prognosis.
conclusionBioinformatics analysis and IHC validation suggest that ELOVL4 expression may serve as a prognostic biomarker for GC, providing new insights for prognosis prediction and therapeutic target development in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.